Bionexus Gene Lab Stock Performance
| BGLC Stock | USD 3.12 0.10 3.11% |
The firm shows a Beta (market volatility) of 0.12, which signifies not very significant fluctuations relative to the market. As returns on the market increase, BioNexus Gene's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioNexus Gene is expected to be smaller as well. At this point, BioNexus Gene Lab has a negative expected return of -0.78%. Please make sure to confirm BioNexus Gene's maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if BioNexus Gene Lab performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days BioNexus Gene Lab has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's essential indicators remain rather sound which may send shares a bit higher in February 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
| Begin Period Cash Flow | 4.5 M | |
| Total Cashflows From Investing Activities | 418.2 K |
BioNexus Gene Relative Risk vs. Return Landscape
If you would invest 519.00 in BioNexus Gene Lab on October 28, 2025 and sell it today you would lose (207.00) from holding BioNexus Gene Lab or give up 39.88% of portfolio value over 90 days. BioNexus Gene Lab is currently does not generate positive expected returns and assumes 3.1796% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than BioNexus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioNexus Gene Target Price Odds to finish over Current Price
The tendency of BioNexus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.12 | 90 days | 3.12 | about 98.0 |
Based on a normal probability distribution, the odds of BioNexus Gene to move above the current price in 90 days from now is about 98.0 (This BioNexus Gene Lab probability density function shows the probability of BioNexus Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days BioNexus Gene has a beta of 0.12 suggesting as returns on the market go up, BioNexus Gene average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding BioNexus Gene Lab will be expected to be much smaller as well. Additionally BioNexus Gene Lab has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. BioNexus Gene Price Density |
| Price |
Predictive Modules for BioNexus Gene
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BioNexus Gene Lab. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.BioNexus Gene Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. BioNexus Gene is not an exception. The market had few large corrections towards the BioNexus Gene's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BioNexus Gene Lab, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BioNexus Gene within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.74 | |
β | Beta against Dow Jones | 0.12 | |
σ | Overall volatility | 0.59 | |
Ir | Information ratio | -0.25 |
BioNexus Gene Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BioNexus Gene for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BioNexus Gene Lab can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| BioNexus Gene Lab generated a negative expected return over the last 90 days | |
| BioNexus Gene Lab has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 9.51 M. Net Loss for the year was (1.6 M) with profit before overhead, payroll, taxes, and interest of 1.4 M. | |
| BioNexus Gene Lab currently holds about 1.34 M in cash with (2.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 36.0% of the company shares are held by company insiders | |
| Latest headline from zacks.com: Has Acurx Pharmaceuticals Outpaced Other Medical Stocks This Year |
BioNexus Gene Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of BioNexus Stock often depends not only on the future outlook of the current and potential BioNexus Gene's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. BioNexus Gene's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.8 M | |
| Cash And Short Term Investments | 4.4 M |
BioNexus Gene Fundamentals Growth
BioNexus Stock prices reflect investors' perceptions of the future prospects and financial health of BioNexus Gene, and BioNexus Gene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioNexus Stock performance.
| Return On Equity | -0.28 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (0.24) % | |||
| Operating Margin | (0.30) % | |||
| Current Valuation | 4.66 M | |||
| Shares Outstanding | 2.36 M | |||
| Price To Earning | 350.00 X | |||
| Price To Book | 1.08 X | |||
| Price To Sales | 0.78 X | |||
| Revenue | 9.51 M | |||
| EBITDA | (1.42 M) | |||
| Cash And Equivalents | 1.34 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 210.56 K | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 3.79 X | |||
| Cash Flow From Operations | (2.23 M) | |||
| Earnings Per Share | (1.28) X | |||
| Total Asset | 10.43 M | |||
| Retained Earnings | (3.44 M) | |||
About BioNexus Gene Performance
By analyzing BioNexus Gene's fundamental ratios, stakeholders can gain valuable insights into BioNexus Gene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioNexus Gene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioNexus Gene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management primarily in Malaysia. BioNexus Gene Lab Corporation was incorporated in 2017 and is based in Kuala Lumpur, Malaysia with an additional office in Sheridan, Wyoming. Bionexus Gene operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 27 people.Things to note about BioNexus Gene Lab performance evaluation
Checking the ongoing alerts about BioNexus Gene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioNexus Gene Lab help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioNexus Gene Lab generated a negative expected return over the last 90 days | |
| BioNexus Gene Lab has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 9.51 M. Net Loss for the year was (1.6 M) with profit before overhead, payroll, taxes, and interest of 1.4 M. | |
| BioNexus Gene Lab currently holds about 1.34 M in cash with (2.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 36.0% of the company shares are held by company insiders | |
| Latest headline from zacks.com: Has Acurx Pharmaceuticals Outpaced Other Medical Stocks This Year |
- Analyzing BioNexus Gene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioNexus Gene's stock is overvalued or undervalued compared to its peers.
- Examining BioNexus Gene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioNexus Gene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioNexus Gene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioNexus Gene's stock. These opinions can provide insight into BioNexus Gene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioNexus Stock analysis
When running BioNexus Gene's price analysis, check to measure BioNexus Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNexus Gene is operating at the current time. Most of BioNexus Gene's value examination focuses on studying past and present price action to predict the probability of BioNexus Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNexus Gene's price. Additionally, you may evaluate how the addition of BioNexus Gene to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Stocks Directory Find actively traded stocks across global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |